If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Sun, de la Torre & Bibi (2026) study the composition of large mammal faunas in Africa and Eurasia throughout the last 10 million years, finding no evidence of waves of faunal dispersal out of Africa, no evidence that early hominins followed dispersal routes of large herbivores out of Africa, no evidence that dispersal of early hominins into Eurasia coincided with major changes in the functional structure of mammalian communities, and no evidence of signification latitudinal differences of the studied communities. Cantalapiedra et al. (2026) study the diversification trends of African artiodactyls, perissodactyls and proboscideans during the last 23 million years, and interpret the decline of large African herbivores as more likely caused by low speciation rates and by environmental constraints on speciation linked to prolonged aridification of Africa than by elevated extinction rates. Evidence from the study of dental and body mass traits of large herbivores from the Turkana Basin and Tugen Hills, indicating that, unlike individual functional traits of mammals from the studied assemblages, multivariate combinations of traits remained closely aligned with environmental conditions throughout the last 10 million years, is presented by Glöggler et al. (2026); the data and the analytical framework of this study are subsequently reevaluated by Greiner & Dagher (2026), who do not consider the conclusions of the study of Glöggler et al. to be conclusively supported by available data.
From June 2023 to April 2024, Serbian television presenter Bojana Janković (née Nikolić), known for hosting the show City, posted to the internet forum Bluelight that she was bedridden with symptoms consistent with neuroleptic-induced deficit syndrome after receiving six depot injections of paliperidone palmitate (four shots of Invega Sustenna and two shots of Invega Trinza). She wrote: "My main problem is 0 motivation, low energy and anhedonia. Also i have cognitive issues. Beddriden mostly..." The injections were prescribed by her private psychiatrist and friend around the time of her divorce from Ognjen Janković, a member of the hip-hop group Beogradski Sindikat. She died by suicide in Belgrade on April 19, 2024, aged 46.
=== 1849–1950: Early history === Pfizer was founded in 1849 as Charles Pfizer & Company by Charles Pfizer and Charles F. Erhart, two cousins who had immigrated to the United States from Ludwigsburg, Germany. The business produced chemical compounds, and was headquartered on Bartlett Street in Williamsburg, Brooklyn, where it produced an antiparasitic called santonin. This was an immediate success, although it was production of citric acid that led to Pfizer's growth in the 1880s. Pfizer continued to buy property in the area (by now the Williamsburg district of the city of Brooklyn, New York and beginning in 1898, the City of Greater New York) to expand its lab and factory, retaining offices on Flushing Avenue until the 1960s; the Brooklyn plant ultimately closed in 2009. Following its success with citric acid, Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) established their main residences in the nearby Clinton Hill district, known for its concentration of Gilded Age wealth. In 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in Manhattan, presaging the company's expansion to Chicago, Illinois, a year later. By 1906 sales exceeded $3 million. World War I caused a shortage of calcium citrate. Pfizer imported the compound from Italy for the manufacture of citric acid, and due to the disruption in supply, the company began a search for an alternative. They found this in the form of a fungus capable of fermenting sugar to citric acid.
Sources: en.wikipedia.org
Many Irish nationalists sympathised with the Boers as oppressed by British imperialism, much like they viewed themselves. Irish miners already in the Transvaal at the start of the war formed the nucleus of two Irish commandos. The Second Irish Brigade was headed by an Australian of Irish parents, Colonel Arthur Lynch. Groups of Irish volunteers went to fight with the Boers—despite the fact that there were many Irish troops fighting in the British army, including the Royal Dublin Fusiliers. In Britain, the "Pro-Boer" campaign expanded, with writers often idealising the Boer society. The war highlighted the dangers of Britain's policy of non-alignment and deepened her isolation. The 1900 UK general election, also known as the "Khaki election", was called by the Prime Minister, Lord Salisbury, on the back of British victories. There was much enthusiasm for the war at this point, resulting in a victory for the Conservative government. However, support waned as it became apparent the war would not be easy and it dragged on, partially contributing to the Conservatives' spectacular defeat in 1906. There was outrage at scorched earth tactics and conditions in the concentration camps. It became apparent there were serious problems with public health in Britain as up to 40% of recruits in Britain were unfit for conscription, and suffered from medical problems such as rickets and other poverty-related illnesses. This came at a time of increasing concern for the poor in Britain. 22,000 Empire troops were killed.
Upon his return from the U.S., Janež introduced the insulin pump method into clinical practice of treating adult patients with type 1 diabetes in Slovenia. Together with his colleagues from the Department of Endocrinology, Diabetes, and Metabolic Disease at University Medical Centre Ljubljana, Janež co-authored the algorithm used in insulin pump treatment, as well as tutored virtually all Slovenian diabetologists in usage of both insulin pump and glucose sensor. Janež also wrote all of the literature on subjects of functional insulin therapy and insulin pump in Slovenia, with its audiences ranging from diabetologists to patients. In 2008, he established a new unit for functional insulin therapy within the University Medical Centre. Janež also led the effort of forming international standards for interpretation of results obtained with glucose sensor, publishing and presenting these on several international diabetes-related symposiums. Coupled with his previous work in the field of functional insulin therapy and its pilot implementation in Slovenia, Janež went on to introduce this approach to diabetes treatment in other countries.
The fundamental process in photoionization is the absorption of a high-energy photon by the molecule and subsequent ejection of an electron. In direct APPI, this process occurs for the analyte molecule, forming the molecular radical cation M•+. The analyte radical cation can be detected as M•+ or it can react with surrounding molecules and be detected as another ion. The most common reaction is the abstraction of a hydrogen atom from the abundant solvent to form the stable [M+H]+ cation, which is usually the observed ion. In dopant-APPI (or photoionization-induced APCI), a quantity of photoionizable molecules (e.g., toluene or acetone) is introduced into the sample stream to create a source of charge carriers. Use of a photoionizable solvent can also achieve the same effect. The dopant or solvent ions can then react with neutral analyte molecules via proton transfer or charge exchange reactions. The above table simplifies the dopant process. In fact, there may be extensive ion-molecule chemistry between dopant and solvent before the analyte becomes ionized. APPI can also produce negative ions by creating a high abundance of thermal electrons from dopant or solvent ionization or by photons striking metal surfaces in the ionization source. The cascade of reactions that can lead to M− or dissociative negative ions [M-X]− often involve O2 as an electron charge carrier. Examples of negative ionization mechanisms include: Direct or dopant-assisted negative ion APPI
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.